

MARRONE BIO INNOVATIONS INC
 Form 3
 December 28, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Vasavada Amit
 (Last) (First) (Middle)

C/O MARRONE BIO INNOVATIONS, INC.,Â 1540 DREW AVENUE
 (Street)

DAVIS,Â CAÂ 95618
 (City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
 12/17/2015

3. Issuer Name and Ticker or Trading Symbol

MARRONE BIO INNOVATIONS INC [MBII]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 VP Research and Development

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)
 Date Exercisable Expiration Date

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)
 Title Amount or Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (1)	03/05/2024	Common Stock	40,000	\$ 14.69	D	Â
Stock Option (Right to Buy)	Â (2)	09/23/2024	Common Stock	12,000	\$ 2.87	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Vasavada Amit C/O MARRONE BIO INNOVATIONS, INC. 1540 DREW AVENUE DAVIS, CA 95618	Â	Â	Â VP Research and Development	Â

Signatures

/s/ Linda V. Moore, as attorney
in-fact

12/28/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of March 24, 2014, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (2) The option vests with respect to 100% of the total shares subject to the option on December 31, 2015.

Â

Remarks:
No securities are beneficially owned. Exhibit list: Exhibit 24 Power of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.